Surgically directed chemotherapy: Heated intraperitoneal lavage with mitomycin C

Fernández-Trigo, Vicente; Stuart, O. Anthony; Stephens, A. D.; Hoover, Louis D.; Sugarbaker, Paul H.

doi:10.1007/978-1-4613-1245-1_6

Cited by 43 publications

(20 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…drug administration [3,4]. Peritoneal lavage with mitomycin C (MMC) results in a drug exposure of the peritoneal surface that is 20 times higher than elsewhere in the body [5,6]. The additional toxic effect of MMC at temperatures higher than 39°C has been demonstrated both in animals and in in vitro models [7,8].…”

Section: Introductionmentioning

confidence: 99%

A new survival model for hyperthermic intraperitoneal chemotherapy (HIPEC) in tumor-bearing rats in the treatment of peritoneal carcinomatosis

et al. 2005

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

A new survival model for hyperthermic intraperitoneal chemotherapy (HIPEC) in tumor-bearing rats in the treatment of peritoneal carcinomatosis

et al. 2005

View full text Add to dashboard Cite

show abstract

“…IP therapy has been under development for several decades and has shown survival benefits in selected patient groups (5,(16)(17)(18)(19)(20). Most studies, conducted in patients with ovarian or gastrointestinal cancer, used IP therapy preoperatively to downstage the disease to facilitate surgical debulking and intraoperatively and postoperatively to treat residual small and microscopic tumors (21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36). Hyperthermia intraoperative IP chemotherapy, where the drug solution (e.g., cisplatin, mitomycin C) is heated to 41-43°C to enhance drug uptake and antitumor efficacy, has also been used.…”

Section: Part I Peritoneal Cancer and Intraperitoneal Cancer Therapymentioning

confidence: 99%

Versatility of Particulate Carriers: Development of Pharmacodynamically Optimized Drug-Loaded Microparticles for Treatment of Peritoneal Cancer

Wientjes

2015

AAPS J

View full text Add to dashboard Cite

Abstract. Intraperitoneal (IP) chemotherapy confers significant survival benefits in cancer patients. However, several problems, including local toxicity and ineffectiveness against bulky tumors, have prohibited it from becoming a standard-of-care. We have developed drug-loaded, tumor-penetrating microparticles (TPM) to address these problems. TPM comprises two components and uses the versatile PLGA or poly(lacticco-glycolic acid) copolymer to provide tumor-selective adherence and pharmacodynamically optimized fractionated dosing to achieve the desired tumor priming (which promotes particle penetration into tumors) plus immediate and sustained antitumor activity. Preclinical studies show that TPM is less toxic and more effective against several IP metastatic tumors with different characteristics (fast vs. slow growing, porous vs. densely packed structures, wide-spread vs. solitary tumors, early vs. late stage, with or without peritoneal carcinomatosis or ascites), compared to the intravenous paclitaxel/ Cremophor micellar solution that has been used off-label in previous IP studies. TPM further requires less frequent dosing. These encouraging preclinical results have motivated the follow-up clinical development of TPM. We are working with National Institutes of Health on the IND-enabling studies.

show abstract

“…

administration [5] and improves patient survival in comparison to palliative systemic chemotherapy [4].We describe a patient who underwent HIPEC. We used a continuous and unaltered infusion of atracurium for muscle relaxation and monitored neuromuscular transmission (NMT) with train-of-four (TOF) responses [6].

…”

mentioning

confidence: 99%

“…administration [5] and improves patient survival in comparison to palliative systemic chemotherapy [4].…”

mentioning

confidence: 99%

Atracurium during induced hyperthermia

et al. 2009

View full text Add to dashboard Cite

During hyperthermic intraperitoneal chemotherapy (HIPEC), we observed a partial recovery from neuromuscular block in a hyperthermic patient after hours of monitored adequate surgical relaxation and continuous infusion of atracurium during normothermia. This recovery is indicative of the higher clearance of atracurium during hyperthermia. This case report emphasizes the clinical relevance of the well-known temperature dependence of the Hofmann elimination of atracurium. Moreover, this report illustrates the importance of monitoring muscle relaxation during HIPEC. Clinicians should be aware that the usual continuous infusion rate of atracurium at 0.3 mg.kg(-1).h(-1) may be inadequate in hyperthermic patients.

show abstract

Surgically directed chemotherapy: Heated intraperitoneal lavage with mitomycin C

Cited by 43 publications

References 9 publications

A new survival model for hyperthermic intraperitoneal chemotherapy (HIPEC) in tumor-bearing rats in the treatment of peritoneal carcinomatosis

A new survival model for hyperthermic intraperitoneal chemotherapy (HIPEC) in tumor-bearing rats in the treatment of peritoneal carcinomatosis

Versatility of Particulate Carriers: Development of Pharmacodynamically Optimized Drug-Loaded Microparticles for Treatment of Peritoneal Cancer

Atracurium during induced hyperthermia

Contact Info

Product

Resources

About